Mignon du Plessis
Overview
Explore the profile of Mignon du Plessis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
du Plessis M, Mikhari R, de Gouveia L, Duma N, Lovelock T, Lawrence C, et al.
Emerg Infect Dis
. 2025 Mar;
31(3):417-426.
PMID: 40023798
We reviewed Corynebacterium spp. infection cases reported in South Africa during 2015-2023. We analyzed 84 isolates from 83 patients with C. diphtheriae, as well as 1 C. belfantii and 3...
2.
Yang Y, Knoll M, Herbert C, Bennett J, Feikin D, Garcia Quesada M, et al.
J Infect
. 2025 Jan;
90(3):106426.
PMID: 39864526
Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13...
3.
Ntozini B, Walaza S, Metcalf B, Hazelhurst S, de Gouveia L, Meiring S, et al.
J Infect Dis
. 2024 Dec;
PMID: 39737783
Background: Group B Streptococcus (GBS) is a leading cause of neonatal meningitis and sepsis and an important cause of disease in adults. Capsular polysaccharide and protein-based GBS vaccines are currently...
4.
Shaw D, Torreblanca R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, et al.
Lancet Digit Health
. 2024 Dec;
PMID: 39709282
Microbiology reference laboratories perform a crucial role within public health systems. This role was especially evident during the COVID-19 pandemic. In this Viewpoint, we emphasise the importance of microbiology reference...
5.
Moyes J, Makhazi M, Walaza S, Ntombela P, Moosa F, von Gottberg A, et al.
Influenza Other Respir Viruses
. 2024 Dec;
18(12):e70034.
PMID: 39648401
Background: Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability...
6.
Cohen C, du Plessis M, Martinson N, Moyes J, Walaza S, Wolter N, et al.
J Infect Dis
. 2024 Nov;
231(2):e328-e336.
PMID: 39542652
Background: Approaches for determining whether influenza vaccination prevents infection, attenuates illness, or both are important for developing improved vaccines. We estimated influenza infection incidence and evaluated symptom ascertainment methodologies in...
7.
Lekhuleni C, Ndlangisa K, Gladstone R, Chochua S, Metcalf B, Li Y, et al.
Nat Commun
. 2024 Sep;
15(1):8401.
PMID: 39333488
Invasive pneumococcal disease (IPD) due to non-vaccine serotypes after the introduction of pneumococcal conjugate vaccines (PCV) remains a global concern. This study used pathogen genomics to evaluate changes in invasive...
8.
Chiwandire N, Walaza S, von Gottberg A, Wolter N, du Plessis M, Moosa F, et al.
Int J Epidemiol
. 2024 Sep;
53(5).
PMID: 39305220
Background: COVID-19 vaccine effectiveness (VE) studies leveraging systematic surveillance in sub-Saharan Africa are limited. We assessed the effectiveness of two vaccines (Pfizer BNT162b2 and Johnson & Johnson Ad26.COV2.S) against SARS-CoV-2-associated...
9.
von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S, Quan V, et al.
Lancet Glob Health
. 2024 Aug;
12(9):e1470-e1484.
PMID: 39151982
Background: In South Africa, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and 13-valent PCV (PCV13) was introduced in 2011, both in a two plus one schedule. We evaluated...
10.
Els F, Kleynhans J, Wolter N, du Plessis M, Moosa F, Tempia S, et al.
S Afr J Infect Dis
. 2024 Aug;
39(1):574.
PMID: 39114258
Background: Comparisons of the characteristics of individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or seasonal influenza in low-to middle-income countries with high human immunodeficiency virus (HIV) prevalence...